Radiochemicals

Iodine-131

Availability · Weekly

8.02 days
Half life
>97.0%
Radiochemical purity
> 160.2 GBq/ml
Concentration
NaI solution
Form

Clinical overview

I-131 major uses include the treatment of thyrotoxicosis (hyperthyroidism) and some types of thyroid cancer that absorb Iodine. I-131 is thus used as direct radioisotope therapy to treat hyperthyroidism caused by Graves’ disease, as well as in hyperactive thyroid nodules. It is also employed as a radioactive label for certain therapeutic radiopharmaceuticals, such as I-131-metaiodobenzylguanidine (I-131-MIBG), used for imaging and treatment of pheochromocytoma and neuroblastoma. In these therapeutic applications, I-131 destroys tissues by emitting short-range beta radiation. Beta radiation is responsible for about 90% of the tissue damage; the isotope’s gamma radiation responds for the remaining destruction. In therapeutic applications, I-131 can also be visualized in diagnostic scans, due to detection of its emitted gamma radiation.

Product data

6 fields · 6 populated

Half life
8.02 days
Radionuclidic purity
> US Pharmacoeias specs
Radiochemical purity
>97.0%
Concentration
> 160.2 GBq/ml
Specific activity
555GBq / mg I (Carrier free)
Form
NaI solution

Weekly supply windows

Calibrated to your delivery date, shipped from qualified reactor and cGMP partners.

Regulatory support

DMF assistance and documentation for Canada, USA and Latin America filings.

Cold-chain logistics

Type A packaging, licensing and customs handled by our regional order desks.

Thinking… Something went wrong. Please try again.